Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones
Open Access
- 1 May 2000
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 45 (5) , 583-590
Abstract
The in vitro activity of the novel 8-methoxyquinolone, moxifloxacin, against Streptococcus pneumoniae was evaluated, and the intracellular targets of this agent were studied. Analysis of mutant strains selected with moxifloxacin demonstrated that first-step mutants bore amino acid substitutions at position 81 in the GyrA subunit of DNA gyrase. This suggests that, unlike older fluoroquinolone agents such as ciprofloxacin and levofloxacin, but similar to other C-8 substituted quinolones like sparfloxacin and gatifloxacin, moxifloxacin targets the GyrA subunit of DNA gyrase as an initial lethal event. Such a mechanism results in high activity against increasingly common S. pneumoniae strains bearing substitutions in DNA topoisomerase IV. Moxifloxacin was active with an MIC of ≤ 0.25 mg/L against S. pneumoniae clinical isolates, and against mutants, selected in the laboratory with ciprofloxacin or levofloxacin, that bore a Ser-79→Phe/Tyr substitution in ParC. The moxifloxacin MIC for strains with mutations in the structural genes for both DNA gyrase subunit GyrA and DNA topoisomerase IV subunit ParC did not exceed 2 mg/L, a level within clinically achievable serum concentrations for this agent. We also found that moxifloxacin is a poor substrate for active efflux in S. pneumoniae. Therefore, the high activity of moxifloxacin against S. pneumoniae appears to be a result of both enhanced activity against DNA gyrase and topoisomerase IV, and reduced efflux from the bacterial cell.Keywords
This publication has 20 references indexed in Scilit:
- Activities of New Fluoroquinolones against Fluoroquinolone-Resistant Pathogens of the Lower Respiratory TractAntimicrobial Agents and Chemotherapy, 1998
- Comparative activity of trovafloxacin and Bay 12-8039 against 452 clinical isolates of Streptococcus pneumoniaeJournal of Antimicrobial Chemotherapy, 1998
- DNA topoisomerase targets of the fluoroquinolones: A strategy for avoiding bacterial resistanceProceedings of the National Academy of Sciences, 1997
- Apparent involvement of a multidrug transporter in the fluoroquinolone resistance of Streptococcus pneumoniaeAntimicrobial Agents and Chemotherapy, 1997
- Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolonesAntimicrobial Agents and Chemotherapy, 1997
- Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitroAntimicrobial Agents and Chemotherapy, 1996
- ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotypeAntimicrobial Agents and Chemotherapy, 1996
- Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniaeAntimicrobial Agents and Chemotherapy, 1996
- Hydrophilicity of quinolones is not an exclusive factor for decreased activity in efflux-mediated resistant mutants of Staphylococcus aureusAntimicrobial Agents and Chemotherapy, 1996
- Destruction of low efficiency markers is a slow process occurring at a heteroduplex stage of transformationMolecular Genetics and Genomics, 1974